Journal
CANCER TREATMENT REVIEWS
Volume 97, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2021.102192
Keywords
HNSCC; PD-1; PD-L1; Immunotherapy
Categories
Funding
- Hellenic Society of Medical Oncologists
Ask authors/readers for more resources
Anti-programmed cell death protein 1 immunotherapy has become the new standard in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the small population that benefits from this therapy calls for drug combinations and novel approaches. HNSCC is highly immunosuppressive, with ongoing research focusing on potential new targets for combination immunotherapy based on emerging clinical and preclinical data.
Anti-programmed cell death protein 1 immunotherapy has become the new standard in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the population that benefits is small, warranting drug combinations and novel approaches. HNSCC is a profoundly immunosuppressive disease, characterized by the interplay among different immune regulatory pathways. As clinical trials evaluating immunotherapy combinations in patients with HNSCC have started producing preliminary results, preclinical evidence on potential new targets for combination immunotherapy continues to accumulate. This review summarizes emerging clinical and preclinical data on immunotherapy combinations for the treatment of HNSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available